NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma
Launched by CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS · Mar 20, 2025
Trial Information
Current as of April 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment for patients with advanced melanoma or sarcoma, which are types of skin and soft tissue cancers. The treatment involves using specially trained immune cells, called T cells, that are directed to target a specific protein (NY-ESO-1) found in some tumors. Patients will receive these T cells along with a mild chemotherapy and low-dose radiation to help the treatment work better. The goal is to see how safe and effective this combination is for patients who have not responded to standard therapies.
To be eligible for this trial, participants must be at least 18 years old and have a confirmed diagnosis of advanced melanoma or sarcoma that expresses the NY-ESO-1 protein. They should have already received and not responded to at least one prior treatment. Patients will undergo a procedure called apheresis to collect their immune cells, which will then be modified and infused back into their bodies. Throughout the trial, participants will be monitored closely for any side effects and to assess how well the treatment is working. It's important to note that there are specific health conditions that may exclude someone from participating, so discussing eligibility with a healthcare provider is essential.
Gender
ALL
Eligibility criteria
- • Inclusion criteria at pre-screening step-1 1) Patients with histologically confirmed advanced or metastatic cutaneous melanoma or any type of sarcoma.
- • Inclusion criteria at pre-screening step-2
- • 1) Immunohistochemically documented NY-ESO-1 expression, defined as ≥ 1+ expression on either archival or fresh tumor tissue by immunohistochemistry, in ≥50% of the sampled tumor tissue.
- • Inclusion criteria at screening
- • 1. Patients with sarcoma, who have received at least one line of standard therapy (if available) and failed to respond, progressed or were intolerant to that therapy, will be eligible. If the participant refuses or is, in the opinion of the investigator, ineligible for these treatments, the reason must be documented in the medical record.
- 2. Patients with metastatic melanoma:
- • 1. Without proto-oncogene B-Raf (BRAF) mutation who have received at least one line of standard therapy and failed to respond, progressed or were intolerant to that therapy, will be eligible. If the participant refuses or is, in the opinion of the investigator, ineligible for these treatments, the reason must be documented in the medical record.
- • 2. With BRAF mutation who have received at least two lines of standard therapy and failed to respond, progressed or were intolerant to that therapy, will be eligible. If the participant refuses or is, in the opinion of the investigator, ineligible for these treatments, the reason must be documented in the medical record.
- • 3. Patient must be HLA-A\*0201 and/or HLA-A\*0205 positive, as identified by high-resolution genomic deoxyribonucleic acid (DNA) typing of the HLA-A locus.
- • 4. Age ≥ 18 years
- • 5. Able to undergo apheresis
- • 6. At least one lesion accessible to biopsy for translational research (TR) at D30, without putting the patient at unusual risk.
- • 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
- • 8. Life expectancy of greater than 12 weeks.
- • 9. Radiologically measurable disease (as per RECIST v1.1).
- • 10. Adequate organ function
- Exclusion Criteria:
- • 1. Patients with an active second malignancy
- • 2. Patients with symptomatic and/or untreated brain metastases, as well as leptomeningeal carcinomatosis. Patients with definitively treated brain metastases will be considered for enrolment after agreement with the Principal Investigator, as long as lesions are stable, there are no new brain lesions, and the patient does not require chronic corticosteroid treatment.
- • 3. History of idiopathic pulmonary fibrosis or evidence of active pneumonitis (any origin). History of radiation pneumonitis in the radiation field (fibrosis) is allowed.
- • 4. History of recent myocardial infarction, or unstable angina, within six months prior to enrolment
- • 5. Patients with prior allogeneic stem cell transplantation or organ transplantation
- • 6. Active severe systemic infections within 2 weeks prior to apheresis
- • 7. Patient requiring regular systemic immunosuppressive therapy. All immunosuppressive medications including but not limited to steroids, mycophenolate mofetil, azathioprine, methotrexate, thalidomide, and anti-Tumor Necrosis Factor-alpha (TNF-alpha) agents must have been discontinued at least 2 weeks before apheresis .
- • 8. History of severe immediate hypersensitivity reaction to any of the agents/ excipients of the study products.
- • 9. Women who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant.
- • 10. Subjects, for whom there are concerns that they will not reliably comply with the requirements for contraception, should not be enrolled into the study.
- • 11. Any serious underlying medical condition that could interfere with study medication and potential adverse events.
About Centre Hospitalier Universitaire Vaudois
The Centre Hospitalier Universitaire Vaudois (CHUV) is a leading academic medical center located in Lausanne, Switzerland, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHUV plays a pivotal role in translating scientific discoveries into transformative therapies, enhancing patient care across a diverse range of medical disciplines. With a multidisciplinary team of experts and state-of-the-art facilities, CHUV is dedicated to fostering collaboration and delivering high-quality evidence that informs clinical practice and policy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lausanne, Vaud, Switzerland
Lausanne, Vd, Switzerland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported